PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.\', \'National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy.\', \'VisMederi S.r.l, Siena, Italy.\', \'VisMederi S.r.l, Siena, Italy; VisMederi Research S.r.l., Siena, Italy.\', \'Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy; Tumour Immunology Unit, Fondazione Toscana Life Sciences, Siena, Italy.\', \'Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.\', \'Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy; University of Turin, Turin, Italy.\', \'Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.\', \'VisMederi Research S.r.l., Siena, Italy.\', \'Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA.\', \'Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Chatham, UK.\', \'MedBiotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.\', \'Department of Medical Biotechnologies, University of Siena, Siena, Italy; Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy.\', \'Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy.\', \'Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA; Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA.\', \'VisMederi S.r.l, Siena, Italy; VisMederi Research S.r.l., Siena, Italy; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.\', \'Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy; Faculty of Medicine, Imperial College, London, UK. Electronic address: rino.r.rappuoli@gsk.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0092-8674(21)00224-510.1016/j.cell.2021.02.035
?:doi
?:hasPublicationType
?:journal
  • Cell
is ?:pmid of
?:pmid
?:pmid
  • 33667349
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 25.137
?:rankingScore_hIndex
  • 682
is ?:relation_isRelatedTo_publication of
?:title
  • Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33667349>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33667349>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all